[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355180-105":59,"doc-detail-355180-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-gutbrainimmune-axis-in-glioma-emerging-mechanisms-and-therapeutic-opportunities","The Gut–Brain–Immune Axis in Glioma - Emerging Mechanisms and Therapeutic Opportunities","","Gliomas, especially glioblastomas, are highly treatment-resistant cancers driven by an immunosuppressive tumor microenvironment and the restrictive blood–brain barrier. Although immunotherapy has advanced peripheral malignancies, effective responses in gliomas remain limited. Increasing evidence links the gut microbiota, via the gut-brain-immune axis, to systemic and central immune regulation, including effects on microglial activation, T cell infiltration, and sensitivity to immune checkpoint inhibitors such as PD-1 and emerging targets (TIM-3, LAG-3, TIGIT). Microbial composition may also influence CAR-T and CAR-NK efficacy. This review synthesizes key preclinical and clinical findings and evaluates gut microbiota modulation strategies as adjuncts to immunotherapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-gutbrainimmune-axis-in-glioma-emerging-mechanisms-and-therapeutic-opportunities/355180/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-gutbrainimmune-axis-in-glioma-emerging-mechanisms-and-therapeutic-opportunities/355180.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are gliomas, especially glioblastomas, resistant to current therapies?","Question",{"text":113,"@type":114},"Gliomas create a profoundly immunosuppressive tumor microenvironment and are constrained by the blood–brain barrier, which together limit effective immune-based treatment and immune surveillance.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the gut-brain-immune axis relate to immune responses in glioma?",{"text":118,"@type":114},"The gut microbiota communicates bidirectionally with the brain and immune system, shaping immune regulation that can affect microglia activation and the infiltration and function of immune cells within glioma.",{"name":120,"@type":111,"acceptedAnswer":121},"What therapeutic opportunities does the review highlight for targeting the gut microbiota?",{"text":122,"@type":114},"The review discusses adjunctive microbiota modulation approaches—such as probiotics, engineered microbes, or fecal microbiota transplantation (FMT)—to potentially enhance immunotherapy outcomes, while also noting translational challenges like interindividual variability and mechanistic uncertainty.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355180,1790571341,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cellular and Molecular Neurobiology (2026) 46:55  \n[https://doi.org/10.1007/s10571-026-01680-3](https://doi.org/10.1007/s10571-026-01680-3)  \nREVIEW PAPER  \nThe Gut–Brain–Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities  \nRidong Feng1 · Zhibo Yang2 · Yueru Zhou3 · Hai Zhao4  \nReceived: 15 September 2025 / Accepted: 21 January 2026 © The Author(s) 2026  \nAbstract  \nGliomas, particularly glioblastomas, represent some of the most treatment-resistant cancers due to their profoundly immunosuppressive tumor microenvironment (TME) and the restrictive nature of the blood–brain barrier. While recent advancesin immunotherapy have transformed the treatment landscape for peripheral tumors, success in gliomas remains limited. Emerging evidence suggests that the gut microbiota—through the gut-brain-immune axis—may play a significant role in shaping systemic and central immune responses. Gut-derived microbial metabolites, immune cell modulation, and neuroimmune signaling pathways have been shown to influence microglial activation, T cell infiltration, and even response to immune checkpoint inhibitors (ICIs) such as PD-1 and emerging targets like TIM-3, LAG-3, and TIGIT. Furthermore, the efficacy and persistence of CAR-T and CAR-NK therapies may also be impacted by microbial composition, offering a novel avenue for therapeutic optimization. This review explores the biological underpinnings of the gut-brain-immune axis in glioma, summarizes key preclinical and clinical findings, and highlights the potential of gut microbiota modulation—via probiotics, engineered microbes, or fecal microbiota transplantation (FMT)—as an adjunct to immunotherapy. We also discuss technical and translational challenges, including interindividual variability and mechanistic uncertainty. Understanding the dynamic crosstalk between the gut and the glioma immune microenvironment may unlock new therapeutic strategies and improve outcomes in this highly lethal disease.  \nKeywords Glioma · Gut-brain-immune axis · Microbiota · Immune checkpoint inhibitors · CAR-T therapy immunosuppressive microenvironment · Microglia  \nRidong Feng and Zhibo Yang have been contributed equally to this work and share first authorship.  \n􀀍 Hai Zhao [yidao@qdu.edu.cn](yidao@qdu.edu.cn)  \n1 Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), 79 Qingchun Rd., Shangcheng District, Hangzhou 330100, Zhejiang, China  \n2 Department of Neurosurgery, 3201 Hospital of Xi’an Jiaotong University Health Science Center, Hanzhong 723000, Shaanxi, China  \n3 Department of Outpatient, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266005, Shandong, China  \n4 Department of Neurosurgery, the Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao 266005, Shandong, China  \nIntroduction  \nGliomas, especially glioblastomas (GBM), are the most common and aggressive primary malignant tumors of the central nervous system (CNS) (Weller et al. 2024) . Despite significant advances in surgery, radiation, and chemotherapy, the prognosis for glioma patients remains poor, with a median survival of approximately 15 months for GBM (Pouyan et al. 2025) . The central challenge in treating gliomas lies in their highly immunosuppressive TME, the existence of the BBB, and their ability to evade immune surveillance (Lin et al. 2024) . These factors contribute to the difficulty of implementing effective immunotherapy in gliomas, which have shown limited response to traditional ICIs, such as anti-PD-1 or anti-CTLA-4 antibodies, that have proven successful in other cancers.  \nRecent evidence suggests that the gut microbiota is emerging as a potential modulator in modulating the immune response to various cancers, including glioma  \n1 3  \n(Nakatsu et al. 2024; BharathwajChetty et al. 2025) . The gut-brain-immune axis, which describes the bidirectional communication between the gut microbiota, the brain, and the immu","cbCaik63w9A5YmtO","https://ap.wps.com/l/cbCaik63w9A5YmtO","pdf",2069492,17,"English","# Introduction\n## Rationale for the gut-brain-immune axis in glioma\n# Core immunological mechanisms\n## Microbial metabolites and immune cell modulation\n## Microbiota effects on immune checkpoint blockade and adoptive cell therapy","[{\"question\":\"Why are gliomas, especially glioblastomas, resistant to current therapies?\",\"answer\":\"Gliomas create a profoundly immunosuppressive tumor microenvironment and are constrained by the blood–brain barrier, which together limit effective immune-based treatment and immune surveillance.\"},{\"question\":\"How does the gut-brain-immune axis relate to immune responses in glioma?\",\"answer\":\"The gut microbiota communicates bidirectionally with the brain and immune system, shaping immune regulation that can affect microglia activation and the infiltration and function of immune cells within glioma.\"},{\"question\":\"What therapeutic opportunities does the review highlight for targeting the gut microbiota?\",\"answer\":\"The review discusses adjunctive microbiota modulation approaches—such as probiotics, engineered microbes, or fecal microbiota transplantation (FMT)—to potentially enhance immunotherapy outcomes, while also noting translational challenges like interindividual variability and mechanistic uncertainty.\"}]","The Gut–Brain–Immune Axis in Glioma - Emerging Mechanisms and Therapeutic Opportunities | PDF",1790116544,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9851b8ac4c94dc0c7df11b820b10fcbc.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc14dbdb2bf90220d7707795d7c9f501.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8d395c0a1b0a13301337fb2215ea778.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c671276cf1cd85f3db7df2103538b5b7.webp",980,1301]